Intellia Therapeutics, Inc

The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety con...

The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.

Intellia Therapeutics, a CRISPR gene-editing biotech company, has surged 70% this year and Wall Street expects another 70% gain over the next 12 months. The company is preparing FDA submission for lonvo-z, a one-time treatment for hereditary angioedema that showed 87% reduction in attacks in phase 3 trials. With positive clinical data and a secon...

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers highe...

Intellia Therapeutics' stock has surged 58% year-to-date following positive phase 3 trial results for lonvo-z, a gene-editing treatment for hereditary angioedema. While lonvo-z shows promise with an 87% reduction in attacks, its commercial opportunity is limited to a small patient population (~7,000 in the U.S.), potentially generating $3.5 billi...